与来自无关供体的骨髓相比，外周血祖细胞的植入更快。

Faster engraftment of peripheral blood progenitor cells compared to bone marrow from unrelated donors.

作者信息

Ringdén O, Hägglund H, Runde V, Basu O, Kroschinsky F, Stockschläder M, Potter M N

机构信息

Department of Clinical Immunology, Huddinge Hospital, Sweden.

出版信息

Bone Marrow Transplant. 1998 Jun;21 Suppl 3:S81-4.

PMID:9712503

Abstract

Twenty-six patients received peripheral blood progenitor cells (PBPC) from unrelated donors at five European Centres. Twenty-five donors were HLA-A, -B and -DR identical and one had a one antigen mismatch. PBPC were mobilised by treatment with G-CSF for 4-5 days. Eleven patients receiving PBPC were compared to 11 patients receiving unrelated bone marrow with comparable prognostic factors. The median mononuclear cell count, the CD3+ cells and the CD56+ cells were seven to 10 times higher in PBPC, compared to bone marrow (P < 0.001). The median CD34+ cell content was 6.1 x 10(6)/kg recipient weight with PBPC, compared to 4.3 with bone marrow (NS). Time from transplantation to neutrophils >0.5 x 10(9)/l was a median of 11 (range 6-21) days using PBPC vs 15 (10-22) days after transplantation of bone marrow (P = 0.03). Transfusions and time to discharge did not differ between the two groups. All 26 patients receiving PBPC engrafted. Acute GVHD grades II-IV was seen in 8/26 (31%) and chronic GVHD in 8/18 (44%). Overall, 13/26 (50%) of the patients are alive and well with a median follow-up of 9 (2-35) months.

摘要

26名患者在欧洲的五个中心接受了来自非亲属供者的外周血祖细胞（PBPC）。25名供者的人类白细胞抗原A、B和DR完全匹配，1名供者有一个抗原错配。通过使用粒细胞集落刺激因子（G-CSF）治疗4 - 5天来动员PBPC。将11名接受PBPC的患者与11名具有可比预后因素的接受非亲属骨髓的患者进行比较。与骨髓相比，PBPC中的单核细胞计数中位数、CD3 +细胞和CD56 +细胞高7至10倍（P < 0.001）。PBPC的CD34 +细胞含量中位数为6.1×10⁶/kg受者体重，而骨髓为4.3（无显著性差异）。使用PBPC从移植到中性粒细胞>0.5×10⁹/L的时间中位数为11天（范围6 - 21天），而骨髓移植后为15天（10 - 22天）（P = 0.03）。两组之间的输血情况和出院时间没有差异。所有26名接受PBPC的患者均植入成功。26例中有8例（31%）出现急性移植物抗宿主病（GVHD）II - IV级，18例中有8例（44%）出现慢性GVHD。总体而言，26例患者中有13例（50%）存活且状况良好，中位随访时间为9个月（2 - 35个月）。